The time - and price - of medical procedures has been exaggerated by doctor group,Post investigation finds How a secretive panel of the American Medical Association distorts doctors’ pay Jul 20 13July 20, 2013Article at washingtonpost.com
Overdoses, bedsores, broken bones: What happened when a private-equity firm sought to care for society’s most vulnerableAfter the Carlyle Group orchestrated a deal for the nation's largest nursing home chain, investors extracted $1.3 billion but left the firm with untenable financial obligations and rising health-code violations. Nov 26 18November 26, 2018Article at washingtonpost.com
When financiers bought up anesthesia practices, they gained the power to hike pricesCreated 10 years ago by a private-equity firm, USAP is now one of the largest in the U.S., with more than 4,000 doctors and spanning nine states. As it gobbled up existing practices, it dominated markets and big price hikes followed. Jun 29 23June 29, 2023Article at washingtonpost.com
A middle-class family’s only option: A $43,000 health insurance premiumConsumers are left with few options and crushing prices as insurers offering Affordable Care Act plans pull out of some regions. Dec 21 25December 21, 2025Article at washingtonpost.com
How Johnson & Johnson companies bred a super poppy to make narcotics for America's most abused opioid pillsJohnson & Johnson, a company more widely known for baby powder and Band-Aids, became a major supplier of narcotic raw materials to the U.S. thanks to poppies engineered in Tasmania. Mar 26 20March 26, 2020Article at washingtonpost.com
Rising painkiller addiction shows damage from drugmakers’ role in shaping medical opinionHow industry-backed pharmaceutical research convinced the FDA that opioids posed "minimal risk" of addiction. Dec 31 12December 31, 2012Article at wapo.st
How pharma funds and publishes "independent" researchEven in the most prestigious of medical journals, industry influence over studies opens door to bias. Nov 25 12November 25, 2012Article at washingtonpost.com
Anemia drug made billions, but at what cost?Anemia drugs generated billions for biotech firm Amgen. But their success was based on company-conducted trials that missed its dangers and touted benefits that years later would be deemed unproven. Jul 20 12July 20, 2012Article at wapo.st